课题基金 / 基金详情

Improving Porcine Islet Function and In Vivo Survival with Lisofylline

Improving Porcine Islet Function and In Vivo Survival with Lisofylline
用利索茶碱改善猪胰岛功能和体内存活率
批准号:
7483549
负责人:
INGRID STUIVER
金额:
$2.02万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2008
资助国家:
美国
项目状态:
已结题
起止时间:
2008-05-01 至 2010-09-12

项目摘要

项目成果

INGRID STUIVER的其他基金

相似基金

相关文献

中文摘要
翻译
描述(申请人提供):微囊化猪(异种)胰岛移植治疗I型糖尿病(T1D)目前被认为是胰岛移植的下一代产品。组织短缺的问题很容易通过使用猪胰岛来解决,然而在各种体内模型中影响移植物存活的免疫成分还没有被容易地定义。在缺乏免疫抑制剂的情况下,将藻酸盐包裹的猪胰岛移植到大鼠和非人灵长类动物的腹膜中时,会出现大量的免疫障碍。我们在MicroIslet,Inc.正在积极研究与早期排斥反应有关的免疫学事件。有趣的是,我们在灵长类动物身上的研究表明,短暂使用传统的T细胞特异性免疫抑制剂,如FK506和雷帕霉素,可以延长移植物存活时间,并使胰岛素需求减少50%-60%。为了优化长期的移植物功能,我们计划研究一种合成的、非糖尿病的、抗炎的甲基-黄嘌呤分子,称为Lisofylline(LSF),它是否会在体内对微囊化猪胰岛移植的存活产生显著的有益影响。 IL-12信号通路通过被称为信号转导和转录激活因子4(STAT4)的主基因开关,在调节免疫反应和自身免疫性疾病的早期阶段起着至关重要的作用。STAT4的激活会导致产生高度致炎细胞因子的基因转录。LSF是一种参与阻断IL-12受体依赖的STAT4激活的小分子。体内和体外研究表明,LSF既能保护胰岛免受细胞因子诱导的凋亡,又能增强胰岛功能。用LSF预处理胰岛可以减少糖尿病动物达到正常血糖所需的移植物大小。在自身免疫紊乱方面,STAT4缺陷的非肥胖糖尿病(NOD)小鼠不会发生自发性糖尿病。短期全身应用LSF可阻止(糖尿病)结节的发病和疾病进展。我们感兴趣的是探索LSF在体内对包裹的猪胰岛的功能增强、细胞保护和免疫调节作用,具体描述如下三个目标。自发性糖尿病NOD小鼠将被用来比较植入藻酸盐包裹的猪胰岛加和不加LSF的免疫学反应。将评估3种不同应用LSF在减少早期体内免疫反应方面的有效性。与公共卫生相关:MicroIslet,Inc.有兴趣探索LSF的短暂使用,或在我们的过程中将LSF与诸如exendin 4的胰岛素模拟物相结合,可能会增强我们产品的性能,包裹猪胰岛,并展示延长移植物功能和存活时间,以实现I型糖尿病的最佳治疗。
英文摘要
DESCRIPTION (provided by applicant): Encapsulated porcine (xeno) islet transplantation for the treatment of Type I Diabetes (T1D) is currently considered to be the next generation product for islet transplantation. The issue of tissue shortage is easily addressed by the use of porcine islets, however the immune component that compromises graft survival in various in vivo models has not been readily defined. A significant number of immunological obstacles arise when transplanting alginate encapsulated porcine islets into the peritoneum of rats and non-human primates in the absence of immunosuppressants. We at MicroIslet, Inc. are actively studying the immunological events involved in the early rejection. Interestingly, our work in primates indicates that transient use of conventional T-cell specific immunosuppressants such as FK506 and Rapamycin confers prolonged graft survival and a 50-60% reduction in insulin requirements. In our effort to optimize long-term graft function we plan to study whether a synthetic, non-diabetogenic, anti- inflammatory methyl-xanthine molecule, termed lisofylline (LSF), will provide a significant beneficial effect in vivo, on the survival of encapsulated porcine islet transplantation. IL-12 signaling path via the master gene switch termed "signal transducers and activators of transcription 4" (STAT 4) is critical for mediating early phases of immune reaction as well as autoimmune diseases. The activation of STAT 4 results in the transcription of genes that produce highly pro-inflammatory cytokines. LSF is a small molecule that participates in blocking IL-12 receptor dependent activation of STAT 4. It has been demonstrated both in vivo and in vitro studies that LSF can protect islets from cytokine induced apoptosis as well as enhance function. Pretreatment of islets with LSF reduces the graft size necessary to achieve normoglycemia in diabetic animals. In terms of autoimmune disorders, STAT 4 deficient non-obese diabetic (NOD) mice do not develop spontaneous diabetes. Short term systemic administration of LSF blocks disease onset and disease progression in (diabetic) NODs. We are interested in exploring the function enhancing, cytoprotective and immunomodulatory effects of LSF on encapsulated porcine islets in vivo as described in the following three Specific Aims. Spontaneously diabetic NOD mice will be used to compare the immunological response to implantation of alginate encapsulated porcine islets with and without LSF. The effectiveness of 3 different applications of LSF on the reduction of the early in vivo immune response will be assessed. PUBLIC HEALTH RELEVANCE: MicroIslet, Inc is interested in exploring the transient utilization of LSF or the combination of LSF and an incretin mimetic such as exendin 4 in our process may enhance the performance of our product, encapsulated porcine islets, and demonstrate prolonged graft function and survival for the optimal treatment of type I diabetes.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
XENOTRANSPLANTATION OF PORCINE ISLETS IN DIABETIC RHESUS MONKEYS
XENOTRANSPLANTATION OF PORCINE ISLETS IN DIABETIC RHESUS MONKEYS
Encapsulated Porcine Islets into Rhesus Macaques
  • 批准号:
    6935036
  • 项目类别:
  • 资助金额:
    $56.24万
  • 财政年份:
    2003
  • 负责人:
    INGRID STUIVER
  • 依托单位:
Encapsulated Porcine Islets into Rhesus Macaques
  • 批准号:
    7280849
  • 项目类别:
  • 资助金额:
    $57.63万
  • 财政年份:
    2003
  • 负责人:
    INGRID STUIVER
  • 依托单位:
海外基金